The Swiss pharmaceutical company InnoMedica defines itself above all by the team's determination to develop medicines from innovative research in the field of nanotransport systems and to bring them to patients based on its own patented technology platform. To achieve this goal, experienced employees work side by side with university graduates and young talents from various fields.
InnoMedica was originally founded in 2000 as a finance company with headquarters in Zug. After various successful investments in the fields of biochemistry and medicine, InnoMedica took a step towards becoming an operationally independent pharmaceutical company in January 2013 with the Targeted Liposomal Doxorubicin project. The acquisition of the Japanese company YAMAZAKI-DDS Co., Ltd. gave InnoMedica access to nanotechnology that had already been researched and patented for over 20 years. The vision of the project is to improve existing drugs in the field of chemotherapy in order to offer cancer patients more gentle alternatives.
Following a rapid development phase of the product, the successful completion of preclinical studies, and the establishment of production in accordance with GMP in Marly near Fribourg, the first patient was treated with InnoMedica's oncology product in November 2018 as part of the first clinical study.
As early as December 2017, InnoMedica protected the second application, which is aimed at the treatment of neurodegenerative diseases such as Parkinson's, with a patent and conducted further research for the drug. In 2020 and 2021, InnoMedica was able to significantly expand the team and further develop the existing infrastructure. Thanks to the fast growth and good progress, the first Parkinson's patient was treated with InnoMedica's neurology drug as part of the NEON study in December 2021.
InnoMedica's current workforce of over 50 employees works at the Nanofactory in Marly near Fribourg or at the offices in Bern. Bern is the workplace of the Finance team and most members of the management. In addition, the Regulatory team, the Clinical Research team, and HR andCommunications are mainly based in Bern. The Nanofactory in Marly is home to the manufacturing teams (Quality Control & Analytics, Quality Assurance, Production, Process Engineering) as well as Research and Development. They are supported by the Supply Chain and the IT department, which ensures a functioning IT infrastructure at both sites.
Learn more about Our Team.
